Trial Profile
An Observational, Cohort study to evaluate the safety and efficacy of Ledipasvir/Sofosbuvir in chronic Hepatitis C GT4-infected patients with advanced liver fibrosis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 18 May 2018
Price :
$35
*
At a glance
- Drugs Ledipasvir/sofosbuvir (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- 18 May 2018 New trial record
- 06 May 2018 Results published in the Journal of Infection